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ing Pubmed between 2002 and 2007 for studies assessing quality
of life as an outcome due to adherence or compliance. Search
terms included were “Diabetes Mellitus Type 2, Compliance,
Medication Adherence” and various combinations of these
terms. There was no speciﬁc criterion to include or exclude
studies. All studies which ﬁt into the purpose for literature review
were analyzed. Patient education was found to be an intervention
that enhances the quality of life. Use of different drug and drug
delivery methods than conventional drugs were also found to
improve quality of life. Age, gender, and treatment problems
associated with insulin are risk factors for discontinuation and
non-adherence to medications. Older patients were found to be
adherent than younger patients. Forgetting to follow regimen,
disruption of routine and adverse effects were some barriers
reported in the literature. The main strategies for medication
adherence were found to be individualized daily routines,
reminder devices such as a day of the week, pillbox, and use of a
special place. There are not many studies done to date to evaluate
the quality of life as an outcome due to adherence and compli-
ance. Further research in this area will help better the under-
standing of relationship between quality of life as an outcome
due to adherence or compliance.
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OBJECTIVE: To develop a classiﬁcation system (CS) for a
diabetes-speciﬁc preference-based measure of health (PBMH).
METHODS: Plausible attributes for the PBMHwere identiﬁed by
Classical Test Theory, using Factor Analysis of responses
from Type 2 Diabetes patients (n = 385) to the 18-item Audit
of Diabetes-Dependent Quality of Life (ADDQoL). A seven-
member expert panel then provided qualitative input for content.
Three pilot rounds in outpatient and community settings pro-
duced data from people with Type 1 and Type 2 diabetes (n1 = 52,
n2 = 65, n3 = 111) that were analyzed usingModern Test Theory,
based onRaschAnalysis (RA), for 1) ﬁt of selected attributes to the
Rasch Model, and 2) scaling of severity levels for attributes.
RESULTS: Principal Axis Factoring with Promax rotation identi-
ﬁed two plausible attributes from six ADDQoL items. In a struc-
tured survey, experts rated the importance of all ADDQoL and
additionally important items, and suggested attributes that might
be described using sets of related items. A CS was developed
consisting of ﬁve independent attributes, with each question con-
taining a description based on the item content of the respective
attribute and four sentences describing severity levels. Maintain-
ing this format, the wording in the CS was further modiﬁed based
on additional input from experts andRA after each pilot. The ﬁnal
attributes were: Physical Ability & Energy, Relationships, Mood
& Feelings, Enjoyment of Diet, and Satisfaction with Manage-
ment of diabetes. Results of the third pilot indicated Inﬁt and
Outﬁt MNSQ for the ﬁve attributes ranging between 0.88 and
1.10. Person and Item reliabilities were 0.65 and 0.92, while the
respective separation ratios were 1.36 and 3.34. Severity levels
usedwere supported byRating Scale Diagnostics indicated byRA.
CONCLUSION: Results of the statistical analyses indicate that
the PBMH has desired psychometric properties. Research on the
estimation of a utility scoring algorithm and validation testing of
this PBMH is ongoing.
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OBJECTIVE: The objective of this study is to quantify the
strength of preferences and likely adherence to therapy of people
with type 2 diabetes mellitus (T2DM) for outcomes of oral
antidiabetic agents (OADs). METHODS: Currently many of the
available OADs for T2DM are associated with side effects such
as weight gain and nausea and vomiting. Understanding patient
preferences for medications with different attributes is important
for predicting likely adherence to OAD treatments with different
side-effects. We developed a web-based instrument to elicit treat-
ment preferences. Inclusion criteria were people 18 years of age
and older who were insulin-naïve and currently taking OADs to
treat T2DM. The instrument included ten stated-choice trade-off
tasks. Subjects chose between pairs of hypothetical medication
alternatives, each including change in HbA1c levels, number
of mild-to-moderate hypoglycemic events per month, water
retention, weight gain in the ﬁrst six months of treatment, mild
stomach upset, and risk of heart attack. Sample sizes were 200 in
the United States and 200 in the UK. RESULTS: The majority of
subjects were white, married, and female. Subjects were willing
to make tradeoffs between all medication attributes. On average,
subjects would accept signiﬁcant weight gain if the medication
yielded a reduction in HbA1c that resulted in optimal control
(6.5%). However, subjects’ stated adherence was signiﬁcantly
lower for treatments with weight gain, increased heart-attack
risk, or persistent nausea and vomiting. The UK sample was less
tolerant of hypoglycemic events. CONCLUSION: While people
with T2DM believe glucose control is important, medication
side-effects inﬂuence patients’ treatment choices. Efﬁcacy as
measured under controlled, clinical-trial conditions may over-
state actual treatment effectiveness as a result of patient concerns
over OAD side effects.
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OBJECTIVE: Few patient-reported outcome measures for
growth hormone (GH) replacement therapy have been formally
validated and none address preference for a particular delivery
method. Our objective was to formally develop a new instru-
ment to assess child and parent satisfaction with and preference
for GH therapy delivery devices. METHODS: An instrument
item pool was generated by combining the following four steps:
1) thorough literature review to identify relevant domains and
questions, 2) consultation with clinicians knowledgeable about
treatment of GH deﬁciency, 3) identiﬁcation of indicators spe-
ciﬁc to GH delivery devices, and 4) input from families with
children aged 10–16 years receiving GH therapy, including both
new (2 to 12 weeks) and established (12 weeks) users. Struc-
tured feedback forms were completed during cognitive inter-
views with focus groups on relevance of questions, missing
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